Fibrodysplasia Ossificans Progressiva Epidemiology Forecast to 2030

April 30 11:20 2020
Fibrodysplasia Ossificans Progressiva Epidemiology Forecast to 2030

DelveInsight has launched a new report on Fibrodysplasia Ossificans Progressiva Epidemiology Forecast to 2030

DelveInsight’s Fibrodysplasia Ossificans Progressiva Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Fibrodysplasia Ossificans Progressiva (FOP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The Fibrodysplasia Ossificans Progressiva (FOP) market report provides current treatment practices, emerging drugs, Fibrodysplasia Ossificans Progressiva (FOP) market share of the individual therapies, current and forecasted Fibrodysplasia Ossificans Progressiva (FOP) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Fibrodysplasia Ossificans Progressiva (FOP) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. This process generally becomes noticeable in early childhood, starting with the neck and shoulders, and proceeding down the body and into the limbs.

                                                       

Click Here- Free sample page

Epidemiology

The Fibrodysplasia Ossificans Progressiva (FOP) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Fibrodysplasia Ossificans Progressiva (FOP) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Fibrodysplasia Ossificans Progressiva (FOP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

 Report key facts-

1. Frederick et al. conducted a study in Philadelphia, United States, titled “Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis,” which stated that the worldwide prevalence of FOP is approximately 1 in 2,000,000. Phenotypic variability in the timing and intensity of flare-ups can be a diagnostic criterion for FOP without evidence of ethnic, racial, gender, or geographic predisposition.

2. According to the European Conference on Rare Diseases, FOP has a prevalence rate of 0.08 per 100,000 people.

3. As per the Delveinsight’sanalysis, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) in the seven major markets was found to be 630 in 2017. In the United States total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) was found to be 293 in 2017.

 Some of key major companies are working on this disease that are given below-

1. Ipsen Pharmaceuticals

2. Regeneron Pharmaceuticals

3. BioCryst Co.

Name of drugs covered which are given below-

1. Palovarotene

2. Garetosmab (REGN2477)

3. BLU-782

Table of content

1. Key Insights 

2. Executive Summary of Fibrodysplasia Ossificans Progressiva (FOP)

3. Fibrodysplasia Ossificans Progressiva (FOP): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Fibrodysplasia Ossificans Progressiva (FOP) Treatment and Management

6.2. Fibrodysplasia Ossificans Progressiva (FOP) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Why should you buy this report?

  • The Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Fibrodysplasia Ossificans Progressiva (FOP) market
  • Quantify patient populations in the global Fibrodysplasia Ossificans Progressiva (FOP) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Fibrodysplasia Ossificans Progressiva (FOP) therapeutics in each of the markets covered
  • Understand the magnitude of Fibrodysplasia Ossificans Progressiva (FOP) population by its epidemiology
  • The Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 Related Reports-

Fibrodysplasia Ossificans Progressiva (FOP) – Market Insight, Epidemiology and Market Forecast – 2028

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories:
view more articles

About Article Author